Table 2.

The baseline study population characteristics according to the quartile of TNFR2

CharacteristicsQuartile of TNFR2, Range, pg/mlP for Linear Trend
Quartile 1 (n=399)Quartile 2 (n=401)Quartile 3 (n=393)Quartile 4 (n=397)
(1186–2248)(2249–2573)(2574–2971)(2972–8253)
Men, %42.445.152.755.7<0.001
Age baseline, yr57.3 (3.8)57.8 (3.9)58.4 (3.8)58.7 (3.7)<0.001
Height, m169.3 (8.9)170.0 (8.6)171.4 (8.2)171.9 (9.0)<0.001
Weight, kg75.6 (14.2)78.1 (13.5)80.9 (13.3)83.6 (15.0)<0.001
Body mass index, kg/m226.3 (3.8)26.9 (3.6)27.5 (3.8)28.2 (4.4)<0.001
hsCRP, mg/L0.91 (0.52–1.58)0.99 (0.57–1.83)1.37 (0.73–2.43)1.59 (0.88–3.47)<0.001
Systolic BP, mmHg127.4 (17.7)130.6 (18.0)128.5 (17.1)131.1 (17.1)0.02
Diastolic BP, mmHg82.5 (10.1)83.9 (10.2)83.1 (9.6)83.9 (9.2)0.13
Fasting glucose, mg/dl95.79 (8.83)95.50 (8.63)95.86 (8.13)96.07 (9.09)0.49
Hemoglobin A1c, %5.52 (0.32)5.53 (0.33)5.51 (0.33)5.57 (0.35)0.09
HDL cholesterol, mg/dl63.83 (16.28)62.01 (15.33)56.85 (16.01)54.44 (15.64)<0.001
LDL cholesterol, mg/dl140.44 (35.44)142.61 (30.57)140.23 (34.01)142.83 (32.49)0.52
Triglycerides, mg/dl79.7 (62.0–106.2)88.5 (62.5–123.9)97.4 (70.8–132.8)97.4 (70.8–141.6)<0.001
Albumin-to-creatinine ratio, mg/g2.21 (0.88–4.69)2.12 (0.88–5.22)1.57 (0.88–4.34)2.21 (0.88–4.78)0.93
ACEi, %1.50.72.32.50.12
ARB, %7.06.59.4100.05
NSAIDs, %1.51.54.12.30.15
Current smoker, %14182227<0.001
Alcohol consumption, %33322222<0.001
Absolute mGFR, ml/min106.2 (20.0)104.9 (19.0)103.2 (19.7)100.7 (20.8)<0.001
mGFR, ml/min per 1.73 m298.6 (13.8)95.8 (13.0)92.3 (14.0)88.6 (14.5)<0.001
eGFR by CKD-EPI equation, ml/min per 1.73 m2
 eGFRcre97.6 (8.2)95.3 (8.8)94.2 (9.2)92.2 (11.0)<0.001
 eGFRcys112.3 (8.9)108.7 (8.8)104.5 (9.9)96.2 (14.4)<0.001
 eGFRcrecys109.1 (9.4)105.3 (9.4)101.8 (9.7)95.8 (12.5)<0.001
  • The Renal Iohexol-Clearance Survey Follow-Up Study. Numbers are presented as mean (SD), median (interquartile range), and percentage. TNFR2, soluble TNF receptor 2; hsCRP, high-sensitivity C-reactive protein; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; mGFR, measured GFR; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFRcre, eGFR on the basis of creatinine; eGFRcys, eGFR on the basis of cystatin C; eGFRcrecys, eGFR on the basis of creatinine and cystatin C.